Baker Ellis Asset Management LLC Reduces Stock Holdings in Stryker Co. (NYSE:SYK)

Baker Ellis Asset Management LLC lessened its holdings in shares of Stryker Co. (NYSE:SYKFree Report) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,640 shares of the medical technology company’s stock after selling 200 shares during the period. Stryker makes up 1.1% of Baker Ellis Asset Management LLC’s holdings, making the stock its 24th biggest position. Baker Ellis Asset Management LLC’s holdings in Stryker were worth $6,780,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Freedom Wealth Alliance LLC acquired a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. Quarry LP acquired a new position in Stryker during the first quarter worth about $27,000. Rise Advisors LLC raised its holdings in Stryker by 692.9% in the 3rd quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. West Tower Group LLC purchased a new position in Stryker in the 2nd quarter worth approximately $35,000. Finally, Cornerstone Planning Group LLC acquired a new position in shares of Stryker during the 2nd quarter worth approximately $38,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of SYK opened at $351.39 on Thursday. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The firm has a fifty day moving average of $347.58 and a 200-day moving average of $307.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The company has a market cap of $133.69 billion, a price-to-earnings ratio of 42.59, a price-to-earnings-growth ratio of 2.85 and a beta of 0.89.

Stryker (NYSE:SYKGet Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the company earned $3.00 earnings per share. Stryker’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, equities analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on SYK shares. Wells Fargo & Company boosted their target price on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Roth Mkm raised their target price on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and upped their price target for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. Citigroup boosted their price target on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Truist Financial lifted their target price on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $333.62.

Check Out Our Latest Research Report on SYK

Insider Buying and Selling

In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The disclosure for this sale can be found here. Over the last three months, insiders sold 212,109 shares of company stock worth $72,845,768. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.